0001193125-11-319186.txt : 20111122 0001193125-11-319186.hdr.sgml : 20111122 20111122073523 ACCESSION NUMBER: 0001193125-11-319186 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20111118 ITEM INFORMATION: Other Events FILED AS OF DATE: 20111122 DATE AS OF CHANGE: 20111122 FILER: COMPANY DATA: COMPANY CONFORMED NAME: GALECTIN THERAPEUTICS INC CENTRAL INDEX KEY: 0001133416 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 043562325 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-31791 FILM NUMBER: 111220382 BUSINESS ADDRESS: STREET 1: 7 WELLS AVENUE STREET 2: STE 34 CITY: NEWTON STATE: MA ZIP: 02459 BUSINESS PHONE: 617-559-0033 MAIL ADDRESS: STREET 1: 7 WELLS AVENUE STREET 2: STE 34 CITY: NEWTON STATE: MA ZIP: 02459 FORMER COMPANY: FORMER CONFORMED NAME: PRO PHARMACEUTICALS INC DATE OF NAME CHANGE: 20010612 8-K 1 d259986d8k.htm FORM 8-K Form 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

November 18, 2011

Date of Report (Date of earliest event reported)

 

 

GALECTIN THERAPEUTICS INC.

(Exact name of registrant as specified in its charter)

 

 

 

NEVADA   000-32877   04-3562325

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

7 WELLS AVENUE

NEWTON, MASSACHUSETTS

02459

(Address of principal executive offices) (Zip Code)

(617) 559-0033

(Registrant’s telephone number, including area code)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 

Item 8.01. Other Events.

In the Form 10-Q Quarterly Report that Galectin Therapeutics Inc. filed on November 10, 2011, we reported that a dispute arose after the settlement agreement was executed with Custom Equity Research, Incorporated (d/b/a Summer Street Research Partners). Following a hearing, the court enforced the settlement agreement upon the terms and for the amount the parties originally negotiated, and both the lawsuit and FINRA arbitration were dismissed with prejudice on November 18, 2011.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Galectin Therapeutics Inc.
By:  

/s/ Anthony D. Squeglia

  Anthony D. Squeglia
  Chief Financial Officer

Date: November 22, 2011